Document is current
Any future updates will be listed below
-
Authors
Fisher, Karl J.
Kinsey, Robert
Mohamath, Raodoh
Phan, Tony
Liang, Hong
Orr, Mark T.
Lykins, William R. https://orcid.org/0000-0001-5677-8733
Guderian, Jeffrey A.
Bakken, Julie
Argilla, David
Ramer-Denisoff, Gabi
Larson, Elise
Qi, Yizhi
Sivananthan, Sandra
Smolyar, Karina
Carter, Darrick https://orcid.org/0000-0001-5901-3402
Paddon, Christopher J. https://orcid.org/0000-0003-4182-2855
Fox, Christopher B. https://orcid.org/0000-0002-4644-2619
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI135673)
Amyris, Inc.
- License Information
-
More Information
Article History
Received: 28 July 2022
Accepted: 24 January 2023
First Online: 16 February 2023
Competing interests
: C.B.F., C.J.P., and K.J.F. declare no Competing Non-Financial Interests but the following Competing Financial Interests. C.J.P. owns shares and possesses stock options in Amyris, Inc. C.B.F. is an inventor on patents and/or patent applications involving terpenoid emulsion adjuvant formulations. K.J.F. and C.J.P. are inventors on a patent application covering novel compounds for use in adjuvant formulations. All other authors declare no competing interests.
